

## Special Issue

# Hormone Receptors in Genitourinary Tumors

### Message from the Guest Editor

Hormone receptors that bind to specific hormones are known to have widespread physiological functions. Recently, a large body of evidence has emerged suggesting that hormone receptors play a role in the development and progression of various types of malignancies, although their exact functions are not fully characterized. The aim of this Special Issue is to provide an overview of current preclinical and clinical findings indicating the involvement of hormone receptor signals in genitourinary tumors including prostate cancer, as well as renal cancer, upper urinary tract cancer, bladder cancer, and testicular cancer that have not traditionally been considered as endocrine neoplasms. Original research or review articles on signaling related to any hormone receptors in urological tumors would be most welcome.

### Guest Editor

Prof. Hiroshi Miyamoto

Director of Genitourinary Pathology, University of Rochester Medical Center, Rochester, NY, USA

### Deadline for manuscript submissions

closed (31 May 2018)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/10964](https://mdpi.com/si/10964)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)